LARGER VIALS = LARGER SAVINGS PER mg

Thymosin Alpha-1

Thymosin Alpha-1

$58.00
$58.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

Thymosin Alpha-1

Thymosin Alpha-1

$58.00
$58.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

Thymosin Alpha-1 (Tα1) is a synthetic peptide fragment derived from the thymosin fraction of thymic tissue. It has been studied for its immunomodulatory effects, particularly its ability to enhance T-cell function, regulate cytokine production, and support host defense against infections and cancer.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

Thymosin Alpha-1 (Tα1, thymalfasin) is a synthetic 28–amino acid peptide originally isolated from the thymus. It plays a central role in immune regulation, particularly in the maturation and activation of T-lymphocytes and modulation of innate and adaptive immunity. Tα1 is approved in several countries (but not the U.S.) as an immunomodulatory therapy for conditions including hepatitis B, hepatitis C, certain cancers, and immune deficiency states. It has also been investigated in sepsis, autoimmune disease, and viral infections (e.g., influenza, COVID-19).

Structure

  • Type: Synthetic thymic peptide
  • Sequence: 28 amino acids (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH)
  • Molecular Weight: ~3108 Da
  • Mechanism:



    Promotes T-cell differentiation and survival



    Enhances NK cell activity and dendritic cell function



    Modulates cytokine production (↑ IL-2, IFN-γ; ↓ IL-10, TGF-β in some contexts)



    Exerts anti-inflammatory and antiviral effects via immune balance

Research

Viral Infections

  • Approved as an adjunct therapy for chronic hepatitis B and C, improving viral clearance and liver function when combined with antivirals.
  • Studied in influenza, HIV, and COVID-19, where it reduced inflammatory complications and improved immune response.

Oncology

  • Used as an adjuvant in cancer immunotherapy, including melanoma, NSCLC, and hepatocellular carcinoma.
  • Enhances the efficacy of vaccines and checkpoint inhibitors by stimulating T-cell–mediated immunity.

Immunodeficiency

  • Restores immune function in secondary immunodeficiencies due to infection, stress, or chemotherapy.
  • Supports immune homeostasis in aging and chronic disease.

Autoimmune & Inflammatory Disorders

  • May reduce pathological inflammation by restoring Treg/Th17 balance.
  • Investigated in conditions such as psoriasis and rheumatoid arthritis.

Safety Profile

  • Generally well tolerated.
  • Side effects: mild injection site reactions, fatigue, headache.
  • No significant systemic toxicity reported in clinical trials.

Summary

Thymosin Alpha-1 is a potent immunomodulatory peptide that:

  • Enhances T-cell and NK cell activity
  • Approved for chronic viral hepatitis and used in oncology support
  • Studied in autoimmune disease, sepsis, and viral infections including COVID-19
  • Acts as a broad immune regulator and vaccine adjuvant

This peptide is supplied as a lyophilized powder. Store vials at 2–8 °C, protected from light and moisture. For long-term storage, keep unopened vials at −20 °C. After reconstitution, prepare solutions under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Goldstein AL, et al. History and biology of thymosin alpha 1: discovery and therapeutic applications. *Ann N Y Acad Sci*. 2007;1112:1–13. doi:10.1196/annals.1415.000

2. King R, et al. Thymosin alpha 1 as an immune modulator: clinical applications in hepatitis B and C. *Expert Opin Biol Ther*. 2002;2(4):337–344. doi:10.1517/14712598.2.4.337

3. Romani L, et al. Thymosin alpha 1: mechanism of action and therapeutic potential. *Int Immunopharmacol*. 2009;9(3): 360–366. doi:10.1016/j.intimp.2008.11.012

4. Andreone P, et al. Thymosin alpha 1 and peginterferon in chronic hepatitis C. *Gut*. 2004;53(2):166–172. doi:10.1136/gut.2003.016634

5. Rasi G, et al. Thymosin alpha 1 in combination therapy for chronic hepatitis B. *J Viral Hepat*. 1996;3(6):335–341. doi:10.1111/j.1365-2893.1996.tb00161.x

6. Wang FS, et al. Immunomodulatory effects of thymosin alpha 1 in chronic hepatitis B patients. *Hepatology*. 1998;27(2): 444–448. doi:10.1002/hep.510270218

7. Garaci E, et al. Thymosin alpha 1 as an adjuvant in cancer immunotherapy. *Cancer Immunol Immunother*. 2003;52(5): 409–416. doi:10.1007/s00262-003-0372-y

8. Shetty A, et al. Thymosin alpha 1 in immune reconstitution and sepsis management. *Crit Care Med*. 2014;42(2): 389–398. doi:10.1097/CCM.0b013e3182a272c4

9. Wu J, et al. Thymosin alpha 1 in COVID-19: immunomodulation and clinical outcomes. *Front Immunol*. 2020;11: 568759. doi:10.3389/fimmu.2020.568759

10. Costantini C, et al. Thymosin alpha 1 as a vaccine adjuvant: immune-enhancing properties. *Expert Rev Vaccines*. 2010;9(6): 639–648. doi:10.1586/erv.10.52